Rotterdam-based startup IMcoMET works in the medical sector, specializing in the development of solutions to fight cancer, particularly skin cancer. To do this, the company extracts interstitial fluid, filled with biomarkers, from the skin in a localized manner, to study it and improve dermatological diagnosis. The aim is to advance biomedical research and provide personalized solutions. Furthermore, to achieve this goal, the start-up relies on 3D printing, and more specifically on microprinting solutions from American manufacturer Boston Micro Fabrication (BMF). Thanks to BMF’s 3D printers, IMcoMET is able to develop microneedle technology, enabling it to extract this famous liquid in a precise, localized manner.